Essay Contest Spotlights Malaria in Kenya
Students in Siaya, Western Kenya, reflect on the various ways the disease has affected their families.
View the slide show »
Partnering with us
We are pursuing a range of vaccine development approaches with an expanding circle of industry, academic, and government partners.
Our portfolio
We maintain a diverse portfolio of projects, including preclinical feasibility studies, translational projects, and one advanced clinical project.
What we do and how we do it
We identify potentially promising malaria vaccine approaches and systematically move them through the development process. At the same time, we work to catalyze access to a successful malaria vaccine in the countries that need it most.
GSK announces EU regulatory submission for RTS,S malaria vaccine candidate
The regulatory application to the European Medicines Agency (EMA) will follow the Article 58 procedure, which allows the EMA to assess the quality, safety and efficacy of a candidate vaccine, or medicine, manufactured in a European Union (EU) member state for a disease recognized by the World Health Organization as of major public health interest, but intended exclusively for use outside the EU.
MVI Names New Director of Research & Development
Dr. Rick King is an accomplished scientist with more than 25 years of experience in the public and private sectors, in both for-profit and nonprofit organizations.
Joint statement from MVI, International AIDS Vaccine Initiative, Aeras
It’s time for AIDS, TB and malaria to go the way of smallpox and polio.
ASTMH 63nd Annual Meeting
November 2–6, 2014
"Investing in the future to defeat malaria.” 
Phase 3 trial of RTS,S/AS01 malaria vaccine in African infants
Twitter
Flickr